A Phase 3 interventional study of SHR-A1912 Injection and Rituximab Injection in Diffuse Large B-cell Lymphoma, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Active, not recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China — 143 open to participants now, 165 under way, 31 of them phase 3. Lymphoma, Large B-Cell, Diffuse · China.
Among the 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China, this one is the 39th largest by enrollment of the 277 interventional ones that give a count, is one of 37 that started in 2025, is one of 57 in phase 3, reaches primary completion later than 92 of the 164 other live ones, and was the 251st registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →143 of the 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China are open now. Recruiting first, the newest first:
Zhujiang Hospital · Sites in China
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18+
The First Hospital of Jilin University · Sites in China
Ages 65+
Shanghai Junshi Bioscience Co., Ltd. · Sites in China
Ages 18–75
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
306 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 78 · Phase 2 161 · Phase 3 63 · Phase 4 8
First in 2006; this study’s year is marked. 37 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 282 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 59 across the 277 interventional studies, 175 across the 29 observational. Of the 60 that completed or were terminated, 20 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 306 have an industry lead sponsor. The 10 most frequent:
This study is registered under Suzhou Suncadia Biopharmaceuticals Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 1 study filed under Lymphoma, Large B-Cell, Diffuse — fewer than ten, so there is no comparison to draw.
33 of the studies in Lymphoma, Large B-Cell, Diffuse with a site in China that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04442022Phase 3Karyopharm Therapeutics IncA Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | 2026-12 |
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT06929624Phase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma | 2027-03 |
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
Add all 33 to your calendar (.ics) → With an account.
Among the 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SHR-A1912 Injection · Drug: Rituximab Injection · Drug: Gemcitabine Hydrochloride for Injection · Drug: Oxaliplatin Injection
Drug: Rituximab Injection · Drug: Gemcitabine Hydrochloride for Injection · Drug: Oxaliplatin Injection
SHR-A1912 injection.
Rituximab injection.
Gemcitabine hydrochloride for injection.
Oxaliplatin injection.
Complete response rate (CRR)
Time frame: Up to 1 years following the first dose of the last enrolled patient.
Overall survival (OS)
Time frame: Up to 5 years following the first dose of the last enrolled patient.
Adverse events (AEs)
Time frame: Up to 5 years following the first dose of the last enrolled patient.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Mar 2027, 23 months after the start.
Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's planned 23 months is below that.
Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphoma, Large B-Cell, Diffuse →
Suzhou Suncadia Biopharmaceuticals Co., Ltd. →